Skip to main content

Table 2 Vaccination details and characteristics of reinfused mononuclear cells

From: Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response

Reinfused leukapheresis producta
Patient Tumor weight [gram] Tumor cell yield No. of tumor cells/vaccine No. of nuclear cells % lympocytes % CD3+c %CD4+/%CD8+c
1 11 1.8 × 108 2 × 107 0.9 × 1010 39 81 65/19
2 31 105 × 108 10 × 107 2.1 × 1010 53 79 57/22
3 24 1.9 × 108 1.4 × 107 0.9 × 1010 71 65 52/12
4 b 14 2.8 × 108 n.a. n.a. n.a. n.a. n.a.
  1. aPBMC were reinfused following 3 days of preparative chemotherapy (cyclophosphamide 350 mg/m2 and fludarabine 20 mg/m2)
  2. bpatient withdrew by choice before the treatment phase
  3. cshown as percentage of lymphocytes
  4. n.a. not applicable